Erlotinib

Sold as Terlot, Tarlonib, Pemetrexed glenmark, Tarpib, Erlotinib cipla, Erlocip, Exoneo, Erlotinib adco, Binit, Erlotinib zydus, Tyrec, Egrotib, Tarceva

C₂₂H₂₃N₃O₄393.40 g/mol

N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine

Drag to rotate. Structure from PubChem CID 176870.

Loading Wikipedia summary

Registration

Applicants: 11
Registrations: 34
Schedule source: Consolidated Schedules 06 July 2026

Applicants and registrations

Applicant	Brands	Dosages	Registrations	Schedule	Leaflets
Activo Health (Pty) Ltd	Terlot	100, 150	510125, 510126	S4	None
Ranbaxy (SA) (Pty) Ltd	Tarlonib	150	520725	S4	None
Glenmark Pharmaceuticals South Africa (Pty) Ltd	Pemetrexed glenmark	100 mg	520763.761	S4	None
Eurolab (Pty) Ltd	Tarpib	25 mg, 100 mg, 150 mg	520773, 520774, 520775	S4	None
Cipla Medpro (Pty) Ltd1 of 6 cancelled	Erlotinib cipla, Erlocip	25, 100, 150	540621, 540622, 540623, 540624.621, 540625.622, 540626.623	S4	None
Adcock ingram limited	Exoneo, Erlotinib adco	25 mg, 100 mg, 150 mg	540805, 540806, 540807, 540808.805, 540809.806, 540810.807	S4	PI PIL
Zydus Healthcare (Pty) LtdCertificate held by Zydus Healthcare SA (Pty) Ltd	Binit, Erlotinib zydus	25, 100, 150	540826, 540827, 540828, 540829.826, 540830.827, 540831.828	S4	PI PIL
Kahma Biotech (Pty) Ltd	Tyrec	150	55/26/0662	S4	PI PIL
Juno Pharma SA (Pty) LtdCertificate held by Kahma Biotech (Pty) Ltd	Tyrec	25, 100	550660, 550661	S4	PI PIL
Dr Reddyæs Laboratories (Pty) Ltd	Egrotib	25, 100, 150	560128, 560129, 560130	S4	None
Roche Products (Pty) Ltd	Tarceva	25 mg, 100 mg, 150 mg	A400359, A400360, A400361	S4	None

Variants

Product	Strength and form	Registration	Status	Schedule	Leaflets
Terlot 100 EACH TABLET CONTAINS: ERLOTINIB HYDROCHLORIDE EQUIVALENT TO ERLOTINIB 100,0 mg	100	51012551/26/0125	Registered	S4	None
Terlot 150 EACH TABLET CONTAINS: ERLOTINIB HYDROCHLORIDE EQUIVALENT TO ERLOTINIB 150,0 m	150	51012651/26/0126	Registered	S4	None
Tarlonib 150 EACH TABLET CONTAINS: ERLOTINIB HYDROCHLORIDE EQUIVALENT TO ERLOTINIB 150,0 mg	150	52072552/26/0725	Registered	S4	None
Pemetrexed 100 MG glenmark EACH TABLET CONTAINS: ERLOTINIB HYDROCHLORIDE EQUIVALENT TO ERLOTINIB 25,0 mg	100 mg	520763.76152/26/0763.761	Registered	S4	None
Tarpib 25 MG EACH TABLET CONTAINS: ERLOTINIB HYDROCHLORIDE EQUIVALENT TO ERLOTINIB 25,0 mg	25 mg	52077352/26/0773	Registered	S4	None
Tarpib 100 MG EACH TABLET CONTAINS: ERLOTINIB HYDROCHLORIDE EQUIVALENT TO ERLOTINIB 100,0 mg	100 mg	52077452/26/0774	Registered	S4	None
Tarpib 150 MG EACH TABLET CONTAINS: ERLOTINIB HYDROCHLORIDE EQUIVALENT TO ERLOTINIB 150,0 mg	150 mg	52077552/26/0775	Registered	S4	None
Erlotinib cipla 25 EACH TABLET CONTAINS ERLOTINIB HYDROCHLORIDE 25,0 mg	25	54062154/26/0621	Cancelled	S4	None
Erlotinib cipla 100 EACH TABLET CONTAINS ERLOTINIB HYDROCHLORIDE 100,0 mg	100	54062254/26/0622	Registered	S4	None
Erlotinib cipla 150 EACH TABLET CONTAINS ERLOTINIB HYDROCHLORIDE 150,0 mg	150	54062354/26/0623	Registered	S4	None
Erlocip 25 EACH TABLET CONTAINS ERLOTINIB HYDROCHLORIDE 25,0 mg	25	540624.62154/26/0624.621	Registered	S4	None
Erlocip 100 EACH TABLET CONTAINS ERLOTINIB HYDROCHLORIDE 100,0 mg	100	540625.62254/26/0625.622	Registered	S4	None
Erlocip 150 EACH TABLET CONTAINS ERLOTINIB HYDROCHLORIDE 150,0 mg	150	540626.62354/26/0626.623	Registered	S4	None
Exoneo 25 MG EACH TABLET CONTAINS ERLOTINIB HYDROCHLORIDE EQUIVALENT TO ERLOTINIB 25,0 mg	25 mg	54080554/26/0805	Registered	S4	None
Exoneo 100 MG EACH TABLET CONTAINS ERLOTINIB HYDROCHLORIDE EQUIVALENT TO ERLOTINIB 100,0 mg	100 mg	54080654/26/0806	Registered	S4	None
Exoneo 150 MG EACH TABLET CONTAINS ERLOTINIB HYDROCHLORIDE EQUIVALENT TO ERLOTINIB 150,0 mg	150 mg	54080754/26/0807	Registered	S4	None
Erlotinib 25 MG adco EACH TABLET CONTAINS ERLOTINIB HYDROCHLORIDE EQUIVALENT TO ERLOTINIB 25,0 mg	25 mgTablet	540808.80554/26/0808.805Approved 10 August 2022	Registered	S4	PI PIL
Erlotinib 100 MG adco EACH TABLET CONTAINS ERLOTINIB HYDROCHLORIDE EQUIVALENT TO ERLOTINIB 100,0 mg	100 mgTablet	540809.80654/26/0809.806Approved 10 August 2022	Registered	S4	PI PIL
Erlotinib 150 MG adco EACH TABLET CONTAINS ERLOTINIB HYDROCHLORIDE EQUIVALENT TO ERLOTINIB 150,0 mg	150 mgTablet	540810.80754/26/0810.807Approved 10 August 2022	Registered	S4	PI PIL
Binit 25 EACH TABLET CONTAINS ERLOTINIB HYDROCHLORIDE EQUIVALENT TO ERLOTINIB 25,0 mg	25Tablets	54082654/26/0826Approved 23 August 2022	Registered	S4	PI PIL
Binit 100 EACH TABLET CONTAINS ERLOTINIB HYDROCHLORIDE EQUIVALENT TO ERLOTINIB 100,0 mg	100Tablets	54082754/26/0827Approved 23 August 2022	Registered	S4	PI PIL
Binit 150 EACH TABLET CONTAINS ERLOTINIB HYDROCHLORIDE EQUIVALENT TO ERLOTINIB 150,0 mg	150Tablets	54082854/26/0828Approved 23 August 2022	Registered	S4	PI PIL
Erlotinib zydus 25 EACH TABLET CONTAINS ERLOTINIB HYDROCHLORIDE EQUIVALENT TO ERLOTINIB 25,0 mg	25Tablets	540829.82654/26/0829.826Approved 23 August 2022	Registered	S4	PI PIL
Erlotinib zydus 100 EACH TABLET CONTAINS ERLOTINIB HYDROCHLORIDE EQUIVALENT TO ERLOTINIB 100,0 mg	100Tablets	540830.82754/26/0830.827Approved 23 August 2022	Registered	S4	PI PIL
Erlotinib zydus 150 EACH TABLET CONTAINS ERLOTINIB HYDROCHLORIDE EQUIVALENT TO ERLOTINIB 150,0 mg	150Tablets	540831.82854/26/0831.828Approved 23 August 2022	Registered	S4	PI PIL
Tyrec 150 ERLOTINIB HYDROCHLORIDE	150Tablet	55/26/0662Approved 24 January 2023	Registered	S4	PI PIL
Tyrec 25 ERLOTINIB HYDROCHLORIDE	25Tablet	55066055/26/0660Approved 24 January 2023	Registered	S4	PI PIL
Tyrec 100 ERLOTINIB HYDROCHLORIDE	100Tablet	55066155/26/0661Approved 24 January 2023	Registered	S4	PI PIL
Egrotib 25 EACH TABLET CONTAINS ERLOTINIB HYDROCHLORIDE EQUIVALENT TO ERLOTINIB 25,0 mg	25	56012856/26/0128	Registered	S4	None
Egrotib 100 EACH TABLET CONTAINS ERLOTINIB HYDROCHLORIDE EQUIVALENT TO ERLOTINIB 100,0 mg	100	56012956/26/0129	Registered	S4	None
Egrotib 150 EACH TABLET CONTAINS ERLOTINIB HYDROCHLORIDE EQUIVALENT TO ERLOTINIB 150,0 mg	150	56013056/26/0130	Registered	S4	None
Tarceva 25 MG EACH TABLET CONTAINS ERLOTINIB HYDROCHLORIDE EQUIVALENT TO ERLOTINIB 25,0 mg	25 mg	A400359A40/26/0359	Registered	S4	None
Tarceva 100 MG EACH TABLET CONTAINS ERLOTINIB HYDROCHLORIDE EQUIVALENT TO ERLOTINIB 100,0 mg	100 mg	A400360A40/26/0360	Registered	S4	None
Tarceva 150 MG EACH TABLET CONTAINS ERLOTINIB HYDROCHLORIDE EQUIVALENT TO ERLOTINIB 150,0 mg	150 mg	A400361A40/26/0361	Registered	S4	None

Regulatory status

Where S4 sits on the scale

S0S1S2S3S4S5S6S7S8

Prescription-only medicine.

Schedule 4 covers most ordinary prescription medicines. You need a prescription from an authorised prescriber, such as a doctor or dentist, and a pharmacist dispenses it. Its price, name, pack size and strength can still be told to the public, as long as nothing links it to what it treats.

Schedule S4, matched to the Consolidated Schedules by ingredient, confidence high.

Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.

Consolidated Schedules listings for Erlotinib hydrochloride equivalent to erlotinib

S4: Erlotinib
Consolidated Schedules 06 July 2026, line 6233

Pharmacological class: Cytostatic agents (class 26)

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

SAHPRA documents

Schedule verified from official documents

Schedule Verification

Erlotinib 25 MG adco, Adcock ingram limited is scheduled S4 in its official SAHPRA documents, read with 90% confidence.

Professional information (PI)For healthcare professionalsErlotinib 25 MG adco, Adcock ingram limited Patient information leaflet (PIL)For patients and carersErlotinib 25 MG adco, Adcock ingram limited

These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.

Research articles

Loading PubMed articles

Background